MFAP5 and intrahepatic cholangiocarcinoma: To test whether MFAP5 could be used as an early diagnostic serum index to discriminate ICC from HCC, we performed an exploratory analysis of MFAP5 serum level in a cohort of 32 ICC patients and 13 HCC patients.